Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review

Table 1

Study Characteristics.

	Number of studies (%)
Type of analysis	n (%)
CUA	40 (83)
CEA	5 (10)
CMA	3 (6)
Study population
UC	27 (56)
CD	20 (42)
Both CD and UC	1 (2)
Type of treatments under investigation
Biologic treatments	33 (69)
5-ASA	11 (23)
Immunosuppressant	5 (10)
Surgery	2 (4)
GMA	1 (2)
Study perspective
Healthcare system perspective	47 (98)
Societal	1 (2)
Time horizon
≤1 year	24 (50)
2–5 years	11 (23)
6–10 years	4 (8)
30 years	2 (4)
Lifetime	4 (8)
Not reported	3 (6)
Model structure
Markov model	24 (50)
Decision tree	16 (33)
Markov and decision tree	2 (4)
No model	4 (8)
Not reported	2 (4)

CUA: cost-utility analysis; CEA: cost-effectiveness analyses; CMA: cost-minimisation analysis; GMA: granulocyte-monocyte aphaeresis; UC: ulcerative colitis; CD: Crohn’s disease; 5-ASA: 5-aminosalicylic acid.